A Sacrococcygeal Teratoma (SCT) is a rare medical miracle that occurs in newborn babies, usually in the first month of life. It is an abnormal growth that develops in the area of the baby’s tailbone. It is most often benign, meaning it is non-cancerous, but can also be malignant, or cancerous. In either case, it is a medical emergency that requires immediate attention. SCTs are classified as either type 1 or type 2. Type 1 SCTs are typically benign and occur in the lower portion of the tailbone. Type 2 SCTs are more likely to be malignant and occur higher up in the tailbone. Both types can cause serious health problems for the baby, including breathing difficulties, developmental delays, and even death.
The exact cause of SCT is unknown, but it is believed to be related to genetic factors. It is also thought that environmental factors, such as exposure to certain chemicals or radiation, may play a role.
SCTs are diagnosed through a physical exam and imaging tests such as ultrasound or magnetic resonance imaging (MRI). Treatment depends on the size and type of the tumor, as well as the age and overall health of the baby. For type 1 SCTs, the tumor is usually surgically removed. In some cases, chemotherapy or radiation may be used to shrink the tumor before surgery. For type 2 SCTs, the tumor may be treated with chemotherapy or radiation, or the entire tumor may be surgically removed.
The outlook for babies with SCTs is generally good. With prompt diagnosis and treatment, most babies make a full recovery. However, there is a risk of complications, including infection, bleeding, and organ damage. In some cases, the tumor may recur or spread to other parts of the body.
A Sacrococcygeal Teratoma is a rare medical miracle that can occur in newborn babies. It is classified as either type 1 or type 2, with type 1 being the more common and benign form. Diagnosis and treatment depend on the size and type of the tumor, as well as the age and overall health of the baby. With prompt diagnosis and treatment, most babies make a full recovery, although there is a risk of complications.
1.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
2.
New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.
3.
Research finds stark disparities in treatment and survival time for people with pancreatic cancer
4.
Tumor characteristics found to differ for melanomas in children, teens and young adults
5.
Relationship-building key to addressing oncologist shortages in rural care
1.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
2.
Colon cancer: Risk factors, warning signs and treatment options
3.
Exploring the Latest Advances in Hodgkin's Lymphoma Treatment
4.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
5.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation